Showing 271-280 of 3239 results for "".
- Report: Prescription Dermatological Drug Market Exceeds 21 Billion Dollarshttps://practicaldermatology.com/news/report-prescription-dermatological-drug-market-exceeds-21-billion-dollars/2458870/The worldwide market for prescription dermatological drugs exceeded $21 billion last year, according to a report from Kalorama Information. The market research firm said field of dermatology is currently experiencing a busy and interesting period and, as a result, the range of therapeutic options
- National Psoriasis Foundation Awards Half a Million Dollars in Fellowshipshttps://practicaldermatology.com/news/national-psoriasis-foundation-awards-half-a-million-dollars-in-fellowships/2458922/Eleven early-career physicians each received a one-year, $50,000 National Psoriasis Foundation Medical Dermatology Fellowship to study psoriasis and psoriatic arthritis. These fellowships will help increase the number of scientists studying
- NIH Funding Often Does Not Match Disease Burden for Dermatologic Conditionshttps://practicaldermatology.com/news/nih-funding-often-does-not-match-disease-burden-for-dermatologic-conditions/2458930/A new analysis of funding prioritization by the National Institutes of Health for skin disease offers a glimpse of cutaneous skin disease on a national level, with some disease states being possibly underfunded. Examining the relationship between dermatologic research funding and skin disease bur
- Hair Restoration Doctors Name Best Celebrity Hair, Meeting Convenes October 23https://practicaldermatology.com/news/20131010-hair_restoration_doctors_name_best_celebrity_hair_meeting_convenes_october_23/2459438/Singer/songwriter John Mayer and “Modern Family” star Sofia Vergara are the male and female celebrities with the most sought-after hair, according to results of the International Society of Hair Restoration Surgery (ISHRS) member survey released rec
- Lutikizumab Meets Primary Endpoint in Phase 3 Hidradenitis Suppurativa Trialhttps://practicaldermatology.com/news/lutikizumab-meets-primary-endpoint-in-phase-3-hidradenitis-suppurativa-trial/2488774/AbbVie announced positive topline results from the Phase 3 INTREPID trial evaluating lutikizumab, an investigational dual IL-1α/IL-1β antagonist, in adults and adolescents with moderate-to-severe hidradenitis suppurativa (HS). The randomized, double-blind, placebo-co
- Phase 3 Trial of Oral Minoxidil Formulation Meets Primary Endpoints in Male Pattern Hair Losshttps://practicaldermatology.com/news/phase-3-trial-of-oral-minoxidil-formulation-meets-primary-endpoints-in-male-pattern-hair-loss/2488751/Veradermics announced positive topline results from its Phase 3 Study 304 evaluating VDPHL01, an investigational extended-release oral minoxidil formulation, in men with mild-to-moderate androgenetic alopecia. The randomized, double-blind, placebo-controlled trial met both co-primary endpoints at
- ORKA-001 Shows Sustained Skin Clearance Through Week 28 in Phase 2a Psoriasis Trialhttps://practicaldermatology.com/news/orka-001-shows-sustained-skin-clearance-through-week-28-in-phase-2a-psoriasis-trial/2488711/The investigational IL-23p19 inhibitor ORKA-001 produced high rates of complete skin clearance through week 28 in adults with moderate-to-severe plaque psoriasis who received their last dose at week 4, according to results from the phase 2a EVERLAST-A trial presented in a research poster at the 2
- Science of Skin Urticaria Discussion Highlights Expanding Treatment Options and Need to Measure Disease Controlhttps://practicaldermatology.com/news/science-of-skin-urticaria-discussion-highlights-expanding-treatment-options-and-need-to-measure-disease-control/2488529/The growing treatment armamentarium for chronic spontaneous urticaria (CSU) is giving dermatologists more opportunities to individualize therapy, but effective management begins with fundamentals: selecting and adequately dosing antihistamines, identifyi
- Phase 3 Study Shows Sustained Psoriasis Responses With SSGJ-608https://practicaldermatology.com/news/phase-3-study-shows-sustained-psoriasis-responses-with-ssgj-608/2488143/A phase 3 trial of the investigational interleukin (IL)-17A–targeting monoclonal antibody (SSGJ-608) showed high response rates through 52 weeks among adults with moderate-to-severe plaque psoriasis. Investigators for the double-blind, placebo-controlled trial included 458 adults in the sa
- Monophasic HA Shows Longer-Term Benefit in Nasolabial Fold Correctionhttps://practicaldermatology.com/news/monophasic-ha-shows-longer-term-benefit-in-nasolabial-fold-correction/2488118/A randomized study comparing 2 types of hyaluronic acid (HA) dermal fillers found similar early improvements in moderate-to-severe nasolabial folds (NLFs), with outcomes favoring monophasic HA at 36 weeks. Galinde et al conducted a randomized, controlled, double-blinded, intraindividual st